BOTZ vs XBI
Global X Robotics & Artificial Intelligence ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.68% for BOTZ.
- • BOTZ pays a higher dividend yield (0.62%).
Side-by-side metrics
| Metric | BOTZ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.68% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.62% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $3.44B | $8.30B |
YTD return | 10.07% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.71 | 1.09 |
P/E ratio | 39.66 | — |
Last price | $39.83 | $133.66 |
Inception | — | — |
Issuer | Global X | State Street |
BOTZ top holdings
| ABBN.SW | ABB Ltd | 8.88% |
| 6861.T | Keyence Corp | 8.82% |
| 6954.T | Fanuc Corp | 8.34% |
| NVDA | NVIDIA Corp | 8.21% |
| ISRG | Intuitive Surgical Inc | 6.95% |
| 6273.T | SMC Corp | 4.71% |
| 300124.SZ | Shenzhen Inovance Technology Co Ltd Class A | 4.16% |
| 6383.T | Daifuku Co Ltd | 3.48% |
| 9660.HK | Horizon Robotics Class B | 2.45% |
| GOOGL | Alphabet Inc Class A | 2.41% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About BOTZ
BOTZ (Global X Robotics & Artificial Intelligence ETF) is Robotics, automation, and AI companies globally. Managed by Global X, the fund carries $3.4B in assets under management, an expense ratio of 0.68%, a dividend yield of 0.62%. Its largest holding is ABB Ltd (ABBN.SW), which represents 8.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 6.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.